As seen on The Today Show
Watch a segment on the Today Show in which PearlPAK and other new options for menopause treatment are discussed.
Our patended blend of hormones has been used safely in Europe for over 40 years.
Now patended in the U.S.
Watch a segment on the Today Show in which PearlPAK and other new options for menopause treatment are discussed.
Over 70% of women in menopause experience brain fog. Our neuroscientist-designed Brain Fog Assessment tests different areas of your brain to inform your treatment plan.
Three Simple Steps
– Pick a day and time that is convenient for you
Every patient starts their journey with a virtual consultation with a trusted clinician trained to treat menopause.We take your symptoms seriously, including those related to your brain.
“I was losing my train of thought and could not find the right words. With PearlPAK treatment, I now have no issue with making my points flow smoothly despite interruptions. I also have my full vocabulary back and readily available for use.”
“Playing brain games and solving puzzles have always been fun for me, but I noticed my brain felt tired and I lacked focus. After taking PearlPAK, my concentration significantly improved. My focus is now increased and I’m tackling business challenges more easily. I’m back to playing my games and loving it!”
“I had not noticed my wife’s quick wit had diminished. Sometime after she started taking PearlPAK, her quick wit gradually returned. She makes me laugh again!”
Smarter HRT for Smarter Women
Science shows that earlier treatment leads to better results, Take charge of your brain health today!
© Copyright 2025 CleopatraRX™. All Rights Reserved. View our Privacy Policy.
*PearlPAK™️ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.
CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and is used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product for use as a drug/routine system and/or treatment.
The PearlPAK™️ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.
Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post-menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.
*PearlPAK™ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.
CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product is for use as a drug/routine system and/or treatment.
The PearlPAK™ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.
Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post – menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.